Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

BYSI BeyondSpring Inc

1,70

0,04 (2,41%)

Dernière mise à jour : 19:25:37

Retardé de 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

BeyondSpring (NASDAQ:BYSI)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Plus de graphiques de la Bourse BeyondSpring

BeyondSpring (NASDAQ:BYSI)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025

Plus de graphiques de la Bourse BeyondSpring

Actualités BeyondSpring Inc

Form 3 - Initial statement of beneficial ownership of securities
Mardi 31 Décembre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Vendredi 15 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
Lundi 11 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
Lundi 16 Septembre 2024 ( il y a 4 mois) • GlobeNewswire Inc.

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medici
Mardi 10 Septembre 2024 ( il y a 4 mois) • GlobeNewswire Inc.

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
Mardi 3 Septembre 2024 ( il y a 4 mois) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 29 Août 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mardi 6 Août 2024 ( il y a 5 mois) • Edgar (US Regulatory)

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
Mardi 6 Août 2024 ( il y a 5 mois) • GlobeNewswire Inc.

Form F-3 - Registration statement by foreign private issuers
Mercredi 12 Juin 2024 ( il y a 7 mois) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercredi 12 Juin 2024 ( il y a 7 mois) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Mercredi 12 Juin 2024 ( il y a 7 mois) • Edgar (US Regulatory)

Plus d'articles sur BeyondSpring Inc

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales